We Claim:

1. A process for introducing a suspension or solution of mometasone furoate anhydrous into a metered dose inhaler container, said container having a valve attached thereto, said method comprising the steps of:

a) introducing mometasone furoate anhydrous, a surfactant and a chlorflourocarbon free propellant into a vessel that is held under pressure to form a suspension or solution;

b) circulating said suspension or solution from the vessel through a line which includes a filling head;

c) bringing said filling head into communication with said metered dose inhaler container through said valve of said metered dose inhaler container;

d) introducing a quantity of such suspension or solution into the container from the filling head of the line through said valve of said metered dose inhaler container;

e) withdrawing said filling head from said metered dose inhaler container; and

f) sealing said metered dose inhaler container.

2. The product produced by the process of claim 1.

3. The process of claim 1, wherein the chloroflourocarbon free propellant is selected from the group consisting of HFA 227 and HFA 134a.

4. The process of claim 1, wherein the mometasone furoate anhydrous is micronized, and wherein at least 90% of the mometasone furoate anhydrous has a particle size of less than 10 μm.

5. A process for introducing a suspension or solution of mometasone furoate anhydrous and formoterol fumarate into a metered dose inhaler container, said container having a valve attached thereto, said method comprising the steps of:

a) introducing mometasone furoate anhydrous, formoterol fumarate, a surfactant and a chlorflourocarbon free propellant into a vessel that is held under pressure to form a suspension or solution;

b) circulating said suspension or solution from the vessel through a line which includes a filling head;

c) bringing said filling head into communication with said metered dose inhaler container through said valve of said metered dose inhaler container;

d) introducing a quantity of such suspension or solution into the container from the filling head of the line through said valve of said metered dose inhaler container;

e) withdrawing said filling head from said metered dose inhaler container; and

f) sealing said metered dose inhaler container.

6. The product produced by the process of claim 5.

7. The process of claim 5, wherein the chloroflourocarbon free propellant is selected from the group consisting of HFA 227 and HFA 134a.

8. The process of claim 5, wherein the mometasone furoate anhydrous and formoterol fumarate are micronized, and wherein at least 90% of the mometasone furoate anhydrous and formoterol fumarate has a particle size of less than 10 μm.

9. The product of claim 6, wherein upon actuation of said metered dose inhaler there is dispensed about 100 μg to about 200 μg of mometasone furoate anhydrous and about 6 μg to about 12 μg of formoterol fumarate per dose.

10. A process for introducing a suspension or solution of a compound selected from the group consisting of mometasone furoate anhydrous, formoterol fumarate and combinations thereof, into a metered dose inhaler container, said container having a valve attached thereto, said method comprising the steps of:

a) introducing said compound, a surfactant and a chlorflourocarbon free propellant into a vessel that is held under pressure to form a suspension or solution, wherein said pressure is greater than about 30 psi;

b) circulating said suspension or solution from the vessel through a line which includes a filling head and a double diaphragm pump;

c) bringing said filling head into communication with said metered dose inhaler container through said valve of said metered dose inhaler container;

d) introducing a quantity of such suspension or solution into the container from the filling head of the line through said valve of said metered dose inhaler container;

e) withdrawing said filling head from said metered dose inhaler container; and

f) sealing said metered dose inhaler container.

11. The product produced by the process of claim 10.

12. The process of claim 10, wherein the chloroflourocarbon free propellant is selected from the group consisting of HFA 227 and HFA 134a.

13. The process of claim 10, wherein the compound is micronized, wherein at least 90% of the compound has a particle size of less than 10 μm.

14. A process for introducing a suspension or solution of a compound selected from the group consisting of mometasone furoate anhydrous, formoterol fumarate and combinations thereof, into a metered dose inhaler container, said container having a valve attached thereto, said method comprising the steps of:

a) introducing said compound, surfactant and a chlorflourocarbon free propellant into a vessel that is held under pressure to form a suspension or solution, wherein said pressure is about 10 psi to about 15 psi;

b) circulating said suspension or solution from the vessel through a line which includes a filling head and a double diaphragm pump;

c) bringing said filling head into communication with said metered dose inhaler container through said valve of said metered dose inhaler container;

d) introducing a quantity of such suspension or solution into the container from the filling head of the line through said valve of said metered dose inhaler container;

e) withdrawing said filling head from said metered dose inhaler container; and

f) sealing said metered dose inhaler container.

15. The product produced by the process of claim 14.

16. A process for introducing a suspension or solution of a compound selected from the group consisting of mometasone furoate anhydrous, formoterol fumarate and combinations thereof, into a metered dose inhaler container, said container having a valve attached thereto, said method comprising the steps of:

a) introducing said compound, surfactant and a chlorflourocarbon free propellant into a vessel that is held under pressure to form a suspension or solution, wherein said pressure is greater about 0 psi to about 10 psi;

b) circulating said suspension or solution from the vessel through a line which includes a filling head and a single diaphragm pump;

c) bringing said filling head into communication with said metered dose inhaler container through said valve of said metered dose inhaler container;

d) introducing a quantity of such suspension or solution into the container from the filling head of the line through said valve of said metered dose inhaler container;

e) withdrawing said filling head from said metered dose inhaler container; and

f) sealing said metered dose inhaler container.

17. The product produced by the process of claim 16.